Form 4: Matinas BioPharma Director Evelyn D'An Acquires Stock Options

Director Evelyn D'An acquired stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Summary

• Evelyn D'An, a director of Matinas BioPharma Holdings, Inc., reported the acquisition of stock options.
• The transaction occurred on April 30, 2025.
• D'An acquired 11,600 stock options with an exercise price of $0.59.
• The options vest on April 30, 2026, subject to stockholder approval of the Issuer's 2025 Equity Incentive Plan.
• The 2025 Plan will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025.
• The options expire on April 30, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction. The vesting condition adds a slight element of uncertainty.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The vesting of the options is contingent on stockholder approval of the 2025 Equity Incentive Plan, which introduces uncertainty.

Future Outlook

The vesting of the options is dependent on the approval of the 2025 Equity Incentive Plan at the upcoming annual meeting.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders: Potential dilution if the options are exercised.
• Employees: The 2025 Equity Incentive Plan may impact employee compensation and motivation.

Next Steps

• Stockholder vote on the 2025 Equity Incentive Plan at the annual meeting on June 23, 2025.
• Vesting of the options on April 30, 2026, contingent on stockholder approval.

Key Dates

Keywords

stock options, director, Matinas BioPharma, MTNB, equity incentive plan, beneficial ownership